Peter Lau
0000-0003-1071-7956
6 papers found
Refreshing results…
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Combined BRAF, MEK and CDK4/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma
Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis
Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series
Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
Missing publications? Search for publications with a matching author name.